Jarosław Biliński MD PhD, Assoc. Prof.

Physician, scientist, innovator, and academic teacher at the Medical University of Warsaw, accomplished specialization in hematology at the Department of Hematology, Transplantation and Internal Medicine University Clinical Center of the Medical University of Warsaw. Founder and CEO of Human Biome Institute – being his research commercialization.

Former vice president of the Regional Medical Council in Warsaw. During his medical studies, he was a laureate of many competitions and a Scholarship from the Minister of Science and Higher Education. In 2013 he graduated from the Faculty of Medicine with the highest score of the year at the Collegium Medicum in Bydgoszcz of the Nicolaus Copernicus University in Toruń. He graduated a year before the plan of doctoral studies at the Medical University of Warsaw, and in 2017 he defended his doctoral dissertation with distinction at the First Medical Faculty of the Medical University of Warsaw. Winner of the prestigious Award of the 5th Faculty of Medicine of the Polish Academy of Sciences.

In 2020, he was the winner of the prestigious polish “Golden OTIS” competition in the “scientific debut of the year” category.Also, in 2020, elected as a “Young Ambassador” of the European Society for Blood and Marrow Transplantation (EBMT). In his research work, he deals with topics in the fields of hematology, clinical transplantology, immunology, metagenomics, genetics and cancer response, gut microbiome and its interactions with the host. Author or co-author of 35 publications in scientific journals, including 30 publications in journals from the Journal Citation Reports (JCR) list with Impact Factor, conference summaries and conference reports, including at prestigious international congresses. Also, author of chapters in two scientific monographs.  Impact Factor >210, Hirsch index 13 (Google Scholar), Number of citations >900, Ministry of Science and Education score 2929. Leader of 8 research grants (about 4 million euros in total), co-researcher in the international clinical trials, including study within the framework of the European Society for Blood and Marrow Transplantation (EBMT). In 2024, he obtained the postdoctoral degree.